Latus Bio: Patient-Centric And Product-Oriented Gene Therapy Company Raises $54 Million
By Amit Chowdhry ● May 9, 2024
Latus Bio, a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), announced its launch and an initial closing of $54 million in Series A funding. 8VC and DCVC Bio are leading the funding round. So far, Samsung Life Science Fund (created by Samsung C&T, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation), The Children’s Hospital of Philadelphia Foundation, Benjamin Franklin Technology Partners, Modi Ventures, and Gaingels have joined as syndicate partners.